image
Mobile_image
eyebrow
For pediatric classical Hodgkin lymphoma
headline

Shape what’s possible

content
ADCETRIS, in combination with a chemotherapy regimen called AVEPC (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide), is approved to treat children 2 years of age and older with previously untreated high-risk classical Hodgkin lymphoma.

Find out more about how ADCETRIS works and review the efficacy and safety results in children.
buttons
See study results
headline

About pediatric classical Hodgkin lymphoma

content
Classical Hodgkin lymphoma, also called Hodgkin’s lymphoma, Hodgkin’s disease, or Hodgkin’s, is a type of cancer of the blood. It starts when lymphocytes, a type of white blood cell, grow out of control.

Between 2013 and 2019, the 5-year overall survival rate was 98% for patients younger than 20 years undergoing treatment for their Hodgkin lymphoma. The overall survival rate is the percentage of people in a study who are still alive for a certain period of time after they were diagnosed with or started treatment for a disease, such as cancer.
collection-container
card-grid-container
collection-item-type
core-card, core-text
heading

What is ADCETRIS?

body
ADCETRIS is a targeted treatment called an antibody-drug conjugate. Learn more about how it works.
cta
Discover how ADCETRIS works
heading

How ADCETRIS is given

body
Learn about what to expect when starting ADCETRIS plus AVEPC treatment.
cta
Prepare for treatment
heading

Resources and support

body
Find resources, financial assistance information, and ways to connect with others.
cta
Explore ADCETRIS resources
image
Mobile_image
headline

ADCETRIS is a well-established treatment backed by over a decade of clinical data

content
  • Nearly 1700 patients with certain types of lymphoma received treatment with ADCETRIS across 8 clinical trials
  • Over 67,000 patients in the US and over 183,000 patients worldwide have been treated with ADCETRIS since 2011


Healthcare providers have relied on the extensive clinical study data of ADCETRIS when treating their patients. Researchers continue to investigate ADCETRIS in clinical trials today.

collection-container
content-container
collection-container-variant
2-column
collection-item-type
core-content, core-text
headline

Talk to your doctor about ADCETRIS

content
Communicating openly with your doctor is an important part of making sure that your treatment is right for you. Your appointment is an opportunity to share symptoms, ask questions, and discuss your treatment goals. These resources are designed to help you feel confident and prepared to have those conversations with your healthcare provider.
icon
headline

ADCETRIS patient brochure

content

This brochure is intended to help build knowledge and confidence through a detailed overview of ADCETRIS and can help inform treatment discussions with your doctor.

English

Spanish

icon
headline

Doctor Discussion Guide

content

It’s important to ask questions and share concerns about ADCETRIS treatment with a doctor. The Doctor Discussion Guide can help you navigate the conversation, so you get the most out of your visit. Take this printable PDF with you to your next appointment.

View the guide

headline

Glossary

content
AVEPC: A combination of 5 chemotherapies—combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.